Editas Medicine, Inc.

NasdaqGS:EDIT 주식 리포트

시가총액: US$240.8m

Editas Medicine 경영진

경영진 기준 점검 2/4

Editas Medicine CEO는 Gilmore O’Neill, Jun2022 에 임명되었습니다 의 임기는 3.92 년입니다. 총 연간 보상은 $2.35M, 29.2% 급여 및 70.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $403.88K 가치에 해당하는 회사 주식의 0.17% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 1.7 년과 7.3 년입니다.

핵심 정보

Gilmore O’Neill

최고경영자

US$2.4m

총 보수

CEO 급여 비율29.17%
CEO 재임 기간3.9yrs
CEO 지분 보유율0.2%
경영진 평균 재임 기간1.7yrs
이사회 평균 재임 기간7.3yrs

최근 경영진 업데이트

Recent updates

분석 기사 • May 14

Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)

The analysts covering Editas Medicine, Inc. ( NASDAQ:EDIT ) delivered a dose of negativity to shareholders today, by...
분석 기사 • May 08

Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates

The first-quarter results for Editas Medicine, Inc. ( NASDAQ:EDIT ) were released last week, making it a good time to...
분석 기사 • Nov 13

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

A week ago, Editas Medicine, Inc. ( NASDAQ:EDIT ) came out with a strong set of quarterly numbers that could...
분석 기사 • Nov 05

Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop

Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have retraced a considerable 29% in the last month, reversing a fair...
분석 기사 • Nov 02

Here's Why We're A Bit Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 14

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Summary Gene editing seems like a great idea: instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as CRISPR. I previously covered two companies, CRISPR Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a CRISPR licensee. But it failed twice, with treatments aimed at eye disease and sickle cell disease/beta thalassemia. And its stock suffered badly. With two strikes against it, EDIT is back in the batter’s box. And unlike peers that attack small-population problems, EDIT is swinging at the mass market, high LDL ("bad") cholesterol. It’s way too early to gauge potential success. But given a big target market, pioneering in-the-body editing, and a beaten-down stock, EDIT's reward-risk balance tilts toward ‘Buy.’. Read the full article on Seeking Alpha
분석 기사 • Sep 09

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have been powering on, with a gain of 26...
분석 기사 • Jul 22

There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump

Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have continued their recent momentum with a 42% gain in the last month...
분석 기사 • Jun 17

Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • May 21

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders are no doubt pleased to see that the share price has bounced 28% in...
분석 기사 • Mar 30

Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has softened a substantial 35% over the previous 30 days, handing...
분석 기사 • Mar 13

We're A Little Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 17

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Summary Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vivo CRISPR pipeline is still in the early stages, leading to a temporary “Hold” rating for EDIT stock until more clarity on targeted indications and clinical results is provided. Both companies face high risks, including potential off-target effects and market volatility, requiring cautious investment and risk mitigation strategies. Read the full article on Seeking Alpha
분석 기사 • Nov 20

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has fared very poorly over the last month, falling by a...
분석 기사 • Nov 06

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • Sep 26

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 25

Editas Medicine: A Risk/Reward Worth Considering

Summary Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks. EDIT's current valuation and potential market growth present an attractive investment opportunity, with a speculative yet promising outlook for long-term gains. Read the full article on Seeking Alpha
분석 기사 • Aug 23

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has fared very poorly over the last month, falling by a...
분석 기사 • Aug 10

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

As you might know, Editas Medicine, Inc. ( NASDAQ:EDIT ) last week released its latest second-quarter, and things did...
분석 기사 • May 12

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

As you might know, Editas Medicine, Inc. ( NASDAQ:EDIT ) last week released its latest quarterly, and things did not...
분석 기사 • Apr 23

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

To the annoyance of some shareholders, Editas Medicine, Inc. ( NASDAQ:EDIT ) shares are down a considerable 25% in the...
분석 기사 • Mar 09

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Those holding Editas Medicine, Inc. ( NASDAQ:EDIT ) shares would be relieved that the share price has rebounded 28% in...
Seeking Alpha • Feb 28

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Summary Results from the Editas Medicine, Inc. phase 1/2 studies using reni-cel for the treatment of patients with Sickle-Cell Disease and Transfusion dependent thalassemia are expected in mid-2024 and end of 2024. The global Sickle-Cell Disease treatment market size is expected to be worth $7.79 billion by 2032. The global thalassemia treatment market is expected to reach $1.5 billion by end of 2031. Editas Medicine can overcome competition with owning several CRISPR Cas9 patents and the differentiation of using Cas12a nuclease, which might have greater selectivity and efficiency over Cas9a CRISPR candidates. Read the full article on Seeking Alpha
분석 기사 • Dec 15

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • May 10

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Celebrations may be in order for Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders, with the analysts delivering a...

CEO 보수 분석

Gilmore O’Neill의 보수는 Editas Medicine의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2026n/an/a

-US$109m

Dec 31 2025US$2mUS$687k

-US$160m

Sep 30 2025n/an/a

-US$200m

Jun 30 2025n/an/a

-US$237m

Mar 31 2025n/an/a

-US$251m

Dec 31 2024US$5mUS$667k

-US$237m

Sep 30 2024n/an/a

-US$211m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$2mUS$641k

-US$153m

Sep 30 2023n/an/a

-US$195m

Jun 30 2023n/an/a

-US$206m

Mar 31 2023n/an/a

-US$219m

Dec 31 2022US$9mUS$356k

-US$220m

보상 대 시장: Gilmore의 총 보수(USD2.35M)는 US 시장에서 비슷한 규모 기업의 평균(USD1.74M)보다 높습니다.

보상과 수익: Gilmore의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Gilmore O’Neill (61 yo)

3.9yrs
재임 기간
US$2,353,655
보수

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

리더십 팀

이름직위재임 기간보수지분
Gilmore O’Neill
President3.9yrsUS$2.35m0.17%
$ 403.9k
Amy Parison
Senior VP & CFO1.2yrsUS$821.66k0.0073%
$ 17.7k
Linda Burkly
Executive VP & Chief Scientific Officer2.8yrsUS$1.18m0.029%
$ 70.8k
Feng Zhang
Co-Founder & Scientific Advisory Board Member13.3yrs데이터 없음데이터 없음
George Church
Co-Founder & Scientific Advisory Board Member13.3yrs데이터 없음데이터 없음
Gregory Whitehead
Executive VP and Chief Technical & Quality Officer2.1yrs데이터 없음데이터 없음
Damien Grierson
Senior VP1.3yrs데이터 없음데이터 없음
Tom Love
Vice President of Peopleless than a year데이터 없음데이터 없음
Frank Panaccio
Senior VP & Chief Business Officer1.3yrs데이터 없음데이터 없음
Brieana Buckley
Senior Vice President of Development and Program Leadership1.3yrs데이터 없음데이터 없음
1.7yrs
평균 재임 기간
64.5yo
평균 나이

경험이 풍부한 관리: EDIT의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.7 년) — 신규 팀일 수 있습니다.

이사회 구성원

이름직위재임 기간보수지분
Gilmore O’Neill
Presidentno dataUS$2.35m0.17%
$ 403.9k
Feng Zhang
Co-Founder & Scientific Advisory Board Memberno data데이터 없음데이터 없음
George Church
Co-Founder & Scientific Advisory Board Memberno data데이터 없음데이터 없음
Andrew Hirsch
Independent Director9yrsUS$118.71k0.0020%
$ 4.9k
Jessica Hopfield
Independent Chairman8.3yrsUS$146.21k0.069%
$ 166.5k
Elliott Levy
Independent Director3.1yrsUS$101.21k0%
$ 0
David Scadden
Independent Director7.3yrsUS$99.96k0%
$ 0
Bernadette Connaughton
Independent Director4.6yrsUS$112.46k0%
$ 0
7.3yrs
평균 재임 기간
67yo
평균 나이

경험이 풍부한 이사회: EDIT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.3 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/20 05:12
종가2026/05/20 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Editas Medicine, Inc.는 25명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Jack AllenBaird
Joel BeattyBaird
Alec StranahanBofA Global Research